Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 10Phase 1 6Phase 3 3Phase EARLY_PHASE1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × iberdomide × Clear all
NCT04975997 2026-04-03

EXCALIBER-RRMM

Celgene

Phase 3 Active not recruiting
939 enrolled
Plasma cell

Multiple Myeloma

NCT05827016 2026-03-13

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Bristol-Myers Squibb

Phase 3 Recruiting
1,216 enrolled
Plasma cell

Multiple Myeloma

NCT06216158 2026-02-02

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Recruiting
411 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡